Kiniksa Pharmaceuticals To Report Fourth Quarter And Full-Ye...| MENAFN.COM

Monday, 20 March 2023 06:58 GMT

Kiniksa Pharmaceuticals To Report Fourth Quarter And Full-Year 2022 Financial Results On February 28, 2023

(MENAFN- GlobeNewsWire - Nasdaq)

HAMILTON, Bermuda, Feb. 27, 2023 (GLOBE NEWSWIRE) -- kiniksa pharmaceuticals, ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2023, at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2022 financial results and recent portfolio execution.

A live webcast will be accessible through the Investors & Media section of the company's website at . Individuals interested in participating in the call via telephone may register here . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa's website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's portfolio of immune-modulating assets, ARCALYST, KPL-404, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit .

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ®
Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.